Related Experiment Video
Updated: Jul 4, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Aspirin "resistance".
Norbert Zimmermann1, Artur-Aron Weber, Thomas Hohlfeld
1Federal Institute of Pharmaceutical Agents and Medicinal Products, Bonn, Germany.
Herz
|June 27, 2008
Summary
Aspirin resistance, the inability to inhibit platelet cyclooxygenase-1, increases atherothrombotic event risk. Identifying aspirin resistance is crucial for personalized antiplatelet therapy to improve patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Laboratory Science
Background:
- Clinical studies reveal inconsistent antiplatelet effects of aspirin.
- Aspirin resistance is defined as the failure to inhibit platelet cyclooxygenase-1 (COX-1) and prevent thromboxane A2 (TXA2) formation.
- Distinguishing aspirin resistance from treatment failure is complicated by varied definitions and discordant laboratory diagnostic techniques.
Purpose of the Study:
- To explore the pharmacological mechanisms underlying aspirin resistance.
- To highlight the clinical implications of aspirin resistance on atherothrombotic events.
- To emphasize the need for standardized diagnostic assays for individualized antiplatelet therapy.
Main Methods:
- Review of recent clinical studies and laboratory findings on aspirin resistance.
- Analysis of potential pharmacokinetic and pharmacodynamic causes of aspirin resistance.
- Examination of clinical trial data on the impact of aspirin resistance on patient outcomes.
Main Results:
- Aspirin resistance is associated with a fourfold increased risk of major atherothrombotic events in patients with vascular disease.
- Potential causes include bioavailability issues, increased platelet turnover, drug interactions, comorbidities (hypercholesterolemia, diabetes), alternative platelet activation pathways, and genetic factors.
- Current diagnostic methods for aspirin resistance show discordant results, complicating assessment.
Conclusions:
- Aspirin resistance significantly worsens clinical outcomes in patients with vascular disease.
- Individualized antiplatelet therapy necessitates considering aspirin resistance.
- Development of standardized, cost-effective diagnostic assays is essential for tailoring antiplatelet treatments, potentially involving adjusted aspirin dosage or alternative agents.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Resistance
When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:20Vascular Resistance
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...